Lupin has launched Clonidine Hydrochloride extended-release tablets, 0.1 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Kapvay tablets had annual sales of around $66 million in the US (IQVIA MAT December 2017).
Lupin's Clonidine Hydrochloride ER tablets is the generic equivalent of Concordia International Corp's Kapvay tablets. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
